Viatris Inc. (VTRS) FCF Payout Ratio: 32.87%
Is Viatris Inc.’s FCF payout ratio high or low?
Viatris Inc.'s FCF payout ratio of 32.87% is 35% above its 4-year average of 24.38%, near the high end of its 4-year range (15.91%–32.87%).
13.25% above its 12-month average of 29.02%.
VTRS FCF Payout Ratio Chart
VTRS Average FCF Payout Ratio Chart
VTRS Current vs Average FCF Payout Ratio Chart
VTRS FCF Payout Ratio Metrics
FCF PAYOUT RATIO
32.87%
FCF PAYOUT RATIO AVG TTM
29.02%
FCF PAYOUT RATIO AVG 3Y
26.49%
FCF PAYOUT RATIO AVG 5Y
24.38%
FCF PAYOUT RATIO AVG 10Y
24.38%
FCF PAYOUT RATIO AVG 15Y
23.45%
FCF PAYOUT RATIO AVG 20Y
30.23%
CURRENT VS TTM AVG
+13.25%
CURRENT VS 3Y AVG
+24.06%
CURRENT VS 5Y AVG
+34.83%
CURRENT VS 10Y AVG
+34.83%
CURRENT VS 15Y AVG
+40.16%
CURRENT VS 20Y AVG
+8.72%
Payout Ratio Comparison
FCF Payout Ratio
32.9%
Earnings Payout Ratio
N/A
Dividend Yield
3.12%
FCF Yield
9.46%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $1.94B | $561.20M | 29.0% |
| 2024 | $1.98B | $574.80M | 29.1% |
| 2023 | $2.33B | $575.60M | 24.8% |
| 2022 | $2.51B | $581.60M | 23.2% |
| 2021 | $2.51B | $399.00M | 15.9% |
| 2020 | $550.60M | $0 | 0.0% |
| 2019 | $1.40B | $0 | 0.0% |
| 2018 | $2.09B | $0 | 0.0% |
| 2017 | $1.79B | $0 | 0.0% |
| 2016 | $1.66B | $0 | 0.0% |
| 2015 | $1.65B | $0 | 0.0% |
| 2014 | $689.50M | $0 | 0.0% |
| 2013 | $772.00M | $0 | 0.0% |
| 2012 | $643.69M | $0 | 0.0% |
| 2011 | $440.58M | $0 | 0.0% |
| 2010 | $738.61M | $139.03M | 18.8% |
| 2009 | $450.67M | $139.03M | 30.9% |
| 2008 | $219.33M | $137.50M | 62.7% |
| 2007 | $57.15M | $29.82M | 52.2% |
| 2006 | $312.87M | $49.77M | 15.9% |
| 2005 | $112.97M | $32.26M | 28.6% |
| 2004 | $107.13M | $26.02M | 24.3% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Viatris Inc. FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. FCF Payout Ratio FAQ
- What is the FCF payout ratio for Viatris Inc. (VTRS)?
- The FCF payout ratio for VTRS stock is 32.87%.
- Is Viatris Inc.'s FCF payout ratio high or low?
- Viatris Inc.'s FCF payout ratio of 32.87% is 35% above its 4-year average of 24.38%, near the high end of its 4-year range (15.91%–32.87%).
- What is the TTM average FCF payout ratio for Viatris Inc. (VTRS)?
- The TTM average FCF payout ratio for VTRS stock is 29.02%.
- What is the 3Y average FCF payout ratio for Viatris Inc. (VTRS)?
- The 3Y average FCF payout ratio for VTRS stock is 26.49%.
- What is the 5Y average FCF payout ratio for Viatris Inc. (VTRS)?
- The 5Y average FCF payout ratio for VTRS stock is 24.38%.
- What is the 10Y average FCF payout ratio for Viatris Inc. (VTRS)?
- The 10Y average FCF payout ratio for VTRS stock is 24.38%.
- What is the 15Y average FCF payout ratio for Viatris Inc. (VTRS)?
- The 15Y average FCF payout ratio for VTRS stock is 23.45%.
- What is the 20Y average FCF payout ratio for Viatris Inc. (VTRS)?
- The 20Y average FCF payout ratio for VTRS stock is 30.23%.
Viatris Inc. FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 28.97% |
| 2024-12-31 | 29.08% |
| 2023-12-31 | 24.76% |
| 2022-12-31 | 23.18% |
| 2021-12-31 | 15.91% |
| 2010-12-31 | 18.82% |
| 2009-12-31 | 30.85% |
| 2008-12-31 | 62.69% |
| 2007-12-31 | 52.19% |
| 2006-03-31 | 15.91% |
| 2005-03-31 | 28.56% |
| 2004-03-31 | 24.29% |
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith